From Name:
From Email:
To Name:
To Email:

Optional Message:


Sanuwave completes patient follow-up in phase 3 trial of diabetic foot ulcer treatment

from Ortho Super Site

Sanuwave Health, Inc. a medical technology company focused on noninvasive, biological-response activating devices in regenerative medicine, announced in a press release the completion of patient follow-up in the company's pivotal phase 3, Investigational Device Exemption (IDE) clinical trial with dermaPACE for the treatment of diabetic foot ulcers. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063